Bellicum BPX-601 (Prostate Cancer)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Undergo leukapheresis to collect your white blood cells or T-cells to make the study drug
- Receive lympho-depleting chemotherapy
- Take the study drug along with rimiducid
- Provide tumor tissue
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
- Have bone scans
What is the Condition Being Studied?
Prostate Cancer

Who Can Participate in this Study?

Adults ages 18+ who:

- Are diagnosed with prostate cancer that has spread (metastatic)

- Have received at least one round of previous treatment

- Have never received treatment with CAR T cell or other modified T cell therapies

For more information about who can join this study, please contact the study team at CCI-TrialReferrals@duke.edu or 919-681-6468.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out if an experimental drug called BPX-601 (the study drug) is a safe and effective treatment for your cancer when it's given with another experimental drug called rimiducid. The study drug is custom-made for each participant from their own white blood cells or T-cells. We collect these cells using a procedure called leukapheresis.

Study Details

Full Title
A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects with Previously Treated Advanced Solid Tumors
Principal Investigator

Contacts
Center for Cancer Immunotherapy DCI Clinical Research Team
Protocol Number
IRB:
PRO00109785

NCT:
NCT02744287
ClinicalTrials.gov
View on ClinicalTrials.gov